Aligos Therapeutics Receives Upfront Payment of $25M USD from the Exclusive License Deal of Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

About this update from Aligos Therapeutics, Inc.

Breakthrough Therapy Designation granted for pevifoscorvir sodium in China SOUTH SAN FRANCISCO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that it has received the upfront payment of $25M USD from the exclusive license deal of pevifoscorvir sodium in Greater China with Xiamen Amoytop Biotech Co., Ltd. (Amoytop). In addition, pevifoscorvir sodium was granted Breakthrough Therapy Designation from the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA). Under the terms of the agreement, Aligos is also eligible to receive up to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royalties on net sales in Amoytop's licensed territories. Aligos retains all development and commercialization rights for pevifoscorvir sodium in the United States, Europe, South Korea, Japan, and all other markets. "We are pleased to provide this update on the collaboration with Amoytop," stated Lawrence Blatt, Ph.D., M.B.A., Chairman, President, and Chief Executive Officer of Aligos Therapeutics. "The joint steering committee has been formed, Breakthrough Therapy Designation has been granted for pevifoscorvir sodium in China, and we look forward to the continued progression of this program. In addition, we are continuing to build on our relationship with Amoytop's planned entrance of our antisense oligonucleotide (ASO) ALG-170675 into the clinic in China in the third quarter of 2026. These two drug candidates together demonstrate the promise of next-generation therapies that have the potential to meaningfully change clinical outcomes for patients with chronic HBV infection." Breakthrough Therapy Designation is granted to new drugs that treat serious diseases with preliminary evidence of efficacy. Under this designation, pevifoscorvir sodium is eligible for priority review of a New Drug Application (NDA) in China. About Aligos Aligos Therapeutics, Inc. (NASDAQ: ALGS) is a clinical stage biotechnology company founded with the mission to improve patient outcomes by developing best-in-class therapies for the treatment of liver and viral diseases. Aligos applies its science driven approach and deep R&D exper...

View stock analysis, news, and events for Aligos Therapeutics, Inc.